PB101 Target Overview
Signal 1 (T cell receptor signal), Signal 2 (Co-stimulatory factor), and Signal 3 (cytokine) are required for activation of T cells. It is well known that when only signal 1 is given to T cells without signal 2 (co-stimulatory factor), they become anergic (refractory state).
As for co-stimulatory factors, many studies have been conducted on the CD40L-CD40 axis, and blocking this axis has resulted in successful results in various mouse disease models.
CD40 is expressed on B cells, dendritic cells, macrophages, etc. A typical ligand of CD40 is CD40L (CD154), which is expressed on T cells, platelets, and vascular endothelial cells.
Development of a new anti-CD40 antibody by attempting to develop an excellent anti-CD40 antibody that has the same level of CD40 signaling blocking effect as the anti-CD40L antibody and does not cause serious side effects.
MoA & Indication of PB101
|Target (MoA)||As a humanized monoclonal anti-CD40 antibody that targets CD40 expressed on antigen-presenting cells (B cells, dendritic cells, macrophages), it inhibits T cell activation by blocking CD40L/CD40 binding.|
- Autoimmune disease
- Organ transplant
Distinctive advantage of PB101
High efficiency in blocking of epitope binding (5-15 times compared to competitors).
High affinity (0.45 nM, no further development required)
Non-agonistic properties (pure binding blocking antibody)
Non- or minimal depleting properties (minimize side effects)
Nonhuman primate/human crosslinking (non-clinical/clinical trials possible).
Xenograft (porcine)–human signaling blockade (can be specialized for xenotransplantation)
Novel epitope binding (broad scope of rights)
αCD154 mAb (5C8) counterpart epitope binding (high efficacy expected)
Linear form epitope binding (minimum difference in efficacy due to structural change)